DOI: https://doi.org/10.22141/2308-2097.52.1.2018.130772

Non-alcoholic fatty liver disease: features of metabolic changes at different stages of the disease

Yu.M. Stepanov, N.V. Nedzvetskaya, V.B. Yagmur, I.A. Klenina

Abstract


Background. Non-alcoholic fatty liver disease (NAFLD) is a chronic diffuse liver pathology that includes simple steatosis, non-alcoholic steatohepatitis with the risk of progression to cirrhosis or even hepatocellular carcinoma. There are many causes of hepatic steatosis, but NAFLD is associated primarily with insulin resistance and metabolic syndrome, which gave grounds for considering NAFLD as a hepatic manifestation of the last one. The liver plays a key role in the metabolism of fatty acids and trigly­cerides, providing synthesis, accumulation, secretion and oxidation of fatty acids. With abdominal obesity inherent to metabolic syndrome, an excessive flow of fatty acids from visceral fat through the portal vein into the liver is noted, with the development of steatosis. The accumulation of lipids in the liver triggers a cascade of prooxidant hepatotoxic events that lead to the development of non-alcoholic steatohepatitis and its possible progression. The purpose was to establish the features of metabolic changes at different stages of NAFLD. Materials and methods. The study included patients with NAFLD, who underwent examination and treatment at the department of liver and pancreatic diseases of the Institute of Gastroenterology of the NAMS of Ukraine. All patients underwent ultrasonography of the abdominal organs, standard biochemical tests and evaluation of blood serum level of total cholesterol, b-lipoproteins, triglycerides, low-density lipoproteins, very-low-density lipoproteins, high-density lipoproteins, glucose, insulin and C-peptide. The HOMA index was used to assess insulin resistance. Results. Metabolic changes in the form of insulin resistance and proatherogenic changes pn the lipidogram, which are characteristic for all patients with NAFLD, were more significant in liver steatosis. Conclusions. Results of our study necessitate the mandatory study of lipid and carbohydrate metabolism in patients with NAFLD for timely correction of disorders, which will reduce the progression of this disease.

Keywords


non-alcoholic fatty liver disease; metabolic syndrome; steatosis; steatohepatitis; insulin resistance; lipid metabolism

References


Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M.Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011 Jun;9(6):524-530.e1; quiz e60. doi: 10.1016/j.cgh.2011.03.020.

Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014 Jun;59(6):2188-95. doi: 10.1002/hep.26986.

Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013 Apr;57(4):1357-65. doi: 10.1002/hep.26156.

Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ; NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010 Sep;52(3):894-903. doi: 10.1002/hep.23759.

Lallukka S, Sevastianova K, Perttila J, et al. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia. 2013 Apr;56(4):886-92. doi: 10.1007/s00125-013-2829-9.

Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology. 2008 Aug;48(2):442-8. doi: 10.1002/hep.22376.

Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010 Feb;51(2):454-62. doi: 10.1002/hep.23312.

Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015 May 19;313(19):1973-4. doi: 10.1001/jama.2015.4260.

Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644.

Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003 Apr;37(4):917-23. doi: 10.1053/jhep.2003.50161.

Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010 Oct;59(10):1410-5. doi: 10.1136/gut.2010.213553.

Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016 May;31(5):936-44. doi: 10.1111/jgh.13264.

Kwon YM, Oh SW, Hwang SS, Lee C, Kwon H, Chung GE. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol. 2012 Dec;107(12):1852-8. doi: 10.1038/ajg.2012.314.

Farrell GC, Chitturi S, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007 Jun;22(6):775-7. doi: 10.1111/j.1440-1746.2007.05002.x.

Park BJ, Kim YJ, Kim DH, et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol. 2008 Jun;23(6):900-7. doi: 10.1111/j.1440-1746.2007.05212.x.

Kim D, Park BJ, Kim W, et al. Visceral fat as a strong and independent risk factor of nonalcoholic fatty liver disease. Gastroenterology. 2008;134:A782-А783. doi: 10.1016/S0016-5085(08)63655-0.

van der Poorten D, Milner KL, Hui J, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008 Aug;48(2):449-57. doi: 10.1002/hep.22350.

Yu SJ, Kim W, Kim D, et al. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine (Baltimore). 2015 Dec;94(48):e2159. doi: 10.1097/MD.0000000000002159.

Kim D, Chung GE, Kwak MS, et al. Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016 Jan;14(1):132-8.e4. doi: 10.1016/j.cgh.2015.07.024.

McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity. J Clin Endocrinol Metab. 2011 Nov;96(11):E1756-60. doi: 10.1210/jc.2011-0615.

Du T, Sun X, Yuan G, et al. Lipid phenotypes in patients with nonalcoholic fatty liver disease. Metabolism. 2016 Sep;65(9):1391-8. doi: 10.1016/j.metabol.2016.06.006.

Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014 Nov;2(11):901-10. doi: 10.1016/S2213-8587(14)70032-4.

Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44. doi: 10.1038/nrgastro.2013.41.




Copyright (c) 2018 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта